title: Pentazocine-induced biphasic analgesia in mice.
abstract: Pentazocine (PZ) is well known to act as an opioid mixed agonist-antagonist analgesic. In the present study, we selected the mouse warm plate test condition of 51 +/- 0.5 degrees C instead of 55 +/- 0.5 degrees C to determine the analgesic action of PZ. As a result, i.c.v. PZ produced a biphasic antinociceptive response, while U-50,488H (U-50) and morphine (MRP) showed a monophasic response. Pretreatment with i.c.v. beta-FNA (mu antagonist) antagonized the initial response, whereas the delayed one was antagonized by pretreatment with nor-BNI (kappa antagonist). In addition, pretreatment with NTI (delta antagonist) significantly attenuated the initial response but not the delayed one. These results suggest that the initial and delayed responses may be mediated mainly by mu/delta and kappa receptors, respectively. With regards to the interaction between MRP and PZ, a low dose of PZ antagonized the analgesic action of MRP, while a high dose PZ plus MRP showed the additive effect. Furthermore, tolerance developed almost equally to both initial and delayed responses, indicating that tolerance to the kappa component of PZ may be developed as well as the mu component of action of PZ.
authors.affiliation: Department of Applied Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: M
authors.initials: M
authors.lastname: Narita
authors.forename: M
authors.initials: M
authors.lastname: Misawa
authors.forename: H
authors.initials: H
authors.lastname: Nagase
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000698:Analgesia / Q000379:methods; D000700:Analgesics / Q000008:administration & dosage; D000818:Animals; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004361:Drug Tolerance; D007211:Indoles / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009019:Morphinans / Q000494:pharmacology; D009020:Morphine / Q000008:administration & dosage; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010423:Pentazocine / Q000008:administration & dosage; D011759:Pyrrolidines / Q000008:administration & dosage; D011957:Receptors, Opioid / Q000502:physiology; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D013997:Time Factors
chemical_list: D000700:Analgesics; D007211:Indoles; D009019:Morphinans; D009292:Narcotic Antagonists; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; C051844:norbinaltorphimine; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; C024524:beta-funaltrexamine; D009020:Morphine; C055382:naltrindole; D010423:Pentazocine